Cargando…
The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
INTRODUCTION: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both. The clinical outcomes of continued...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829816/ https://www.ncbi.nlm.nih.gov/pubmed/24260125 http://dx.doi.org/10.1371/journal.pone.0078676 |
_version_ | 1782291395175776256 |
---|---|
author | Wohl, David A. Kendall, Michelle A. Feinberg, Judith Alston-Smith, Beverly Owens, Susan Chafey, Suzette Marco, Michael Maxwell, Sharon Benson, Constance Keiser, Philip van der Horst, Charles Jacobson, Mark A. |
author_facet | Wohl, David A. Kendall, Michelle A. Feinberg, Judith Alston-Smith, Beverly Owens, Susan Chafey, Suzette Marco, Michael Maxwell, Sharon Benson, Constance Keiser, Philip van der Horst, Charles Jacobson, Mark A. |
author_sort | Wohl, David A. |
collection | PubMed |
description | INTRODUCTION: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both. The clinical outcomes of continued ART prescription for such patients have not been well characterized. METHODS: We examined the causes and predictors of all-cause mortality, AIDS-defining conditions, and serious non-AIDS-defining events among a cohort of participants in a clinical trial of pre-emptive therapy for CMV disease. We focused on participants who, despite ART had failed to achieve virologic suppression and substantive immune reconstitution. RESULTS: 233 ART-receiving participants entered with a median baseline CD4+ T cell count of 30/mm(3) and plasma HIV RNA of 5 log(10) copies/mL. During a median 96 weeks of follow-up, 24.0% died (a mortality rate of 10.7/100 patient-years); 27.5% reported a new AIDS-defining condition, and 22.3% a new serious non-AIDS event. Of the deaths, 42.8% were due to an AIDS-defining condition, 44.6% were due to a non-AIDS-defining condition, and 12.5% were of unknown etiology. Decreased risk of mortality was associated with baseline CD4+ T cell count ≥25/mm(3) and lower baseline HIV RNA. CONCLUSIONS: Among patients with advanced AIDS prescribed modern ART who achieve neither virologic suppression nor immune reconstitution, crude mortality percentages appear to be lower than reported in cohorts of patients studied a decade earlier. Also, in contrast to the era before modern ART became available, nearly half of the deaths in our modern-era study were caused by serious non-AIDS-defining events. Even among the most advanced AIDS patients who were not obtaining apparent immunologic and virologic benefit from ART, continued prescription of these medications appears to alter the natural history of AIDS—improving survival and shifting the causes of death from AIDS- to non-AIDS-defining conditions. |
format | Online Article Text |
id | pubmed-3829816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38298162013-11-20 The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit Wohl, David A. Kendall, Michelle A. Feinberg, Judith Alston-Smith, Beverly Owens, Susan Chafey, Suzette Marco, Michael Maxwell, Sharon Benson, Constance Keiser, Philip van der Horst, Charles Jacobson, Mark A. PLoS One Research Article INTRODUCTION: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both. The clinical outcomes of continued ART prescription for such patients have not been well characterized. METHODS: We examined the causes and predictors of all-cause mortality, AIDS-defining conditions, and serious non-AIDS-defining events among a cohort of participants in a clinical trial of pre-emptive therapy for CMV disease. We focused on participants who, despite ART had failed to achieve virologic suppression and substantive immune reconstitution. RESULTS: 233 ART-receiving participants entered with a median baseline CD4+ T cell count of 30/mm(3) and plasma HIV RNA of 5 log(10) copies/mL. During a median 96 weeks of follow-up, 24.0% died (a mortality rate of 10.7/100 patient-years); 27.5% reported a new AIDS-defining condition, and 22.3% a new serious non-AIDS event. Of the deaths, 42.8% were due to an AIDS-defining condition, 44.6% were due to a non-AIDS-defining condition, and 12.5% were of unknown etiology. Decreased risk of mortality was associated with baseline CD4+ T cell count ≥25/mm(3) and lower baseline HIV RNA. CONCLUSIONS: Among patients with advanced AIDS prescribed modern ART who achieve neither virologic suppression nor immune reconstitution, crude mortality percentages appear to be lower than reported in cohorts of patients studied a decade earlier. Also, in contrast to the era before modern ART became available, nearly half of the deaths in our modern-era study were caused by serious non-AIDS-defining events. Even among the most advanced AIDS patients who were not obtaining apparent immunologic and virologic benefit from ART, continued prescription of these medications appears to alter the natural history of AIDS—improving survival and shifting the causes of death from AIDS- to non-AIDS-defining conditions. Public Library of Science 2013-11-15 /pmc/articles/PMC3829816/ /pubmed/24260125 http://dx.doi.org/10.1371/journal.pone.0078676 Text en © 2013 Wohl et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Wohl, David A. Kendall, Michelle A. Feinberg, Judith Alston-Smith, Beverly Owens, Susan Chafey, Suzette Marco, Michael Maxwell, Sharon Benson, Constance Keiser, Philip van der Horst, Charles Jacobson, Mark A. The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit |
title | The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit |
title_full | The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit |
title_fullStr | The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit |
title_full_unstemmed | The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit |
title_short | The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit |
title_sort | clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced aids who manifest no virologic or immunologic benefit |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829816/ https://www.ncbi.nlm.nih.gov/pubmed/24260125 http://dx.doi.org/10.1371/journal.pone.0078676 |
work_keys_str_mv | AT wohldavida theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT kendallmichellea theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT feinbergjudith theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT alstonsmithbeverly theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT owenssusan theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT chafeysuzette theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT marcomichael theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT maxwellsharon theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT bensonconstance theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT keiserphilip theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT vanderhorstcharles theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT jacobsonmarka theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT wohldavida clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT kendallmichellea clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT feinbergjudith clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT alstonsmithbeverly clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT owenssusan clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT chafeysuzette clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT marcomichael clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT maxwellsharon clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT bensonconstance clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT keiserphilip clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT vanderhorstcharles clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT jacobsonmarka clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit AT clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit |